13F Data
13F filer · CIK 1780067

Atlas Venture Associates IX, LLC

BOSTON, MA · filing since Q4 2020 · last filing Feb 11, 2021
Reported value
$631.0M
Positions
7
New / sold out
7 / 0
Added / reduced
0 / 0
Turnover
–
buys $631.0M · sells $0
Top-10 weight
100.0%

No 13F for Q3 2020, so every position this quarter shows as new.

Biggest buys vs Q3 2020

ChangeSecurityShares changeChange %Est. trade value
NewSKILLZ INC+23,284,403–+$465.7M
NewINTELLIA THERAPEUTICS INC+1,615,321–+$87.9M
NewSURFACE ONCOLOGY INC+2,945,453–+$27.2M
NewSPERO THERAPEUTICS INC+1,376,968–+$26.7M
NewCOGENT BIOSCIENCES INC+916,196–+$10.3M
NewSNAP INC+150,160–+$7.5M
NewSYNLOGIC INC+2,651,963–+$5.7M

Biggest sells vs Q3 2020

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2020: $631.0M
Q4 2020Q4 2020

Holdings · Q4 2020

#SecuritySharesValueWeight
1SKILLZ INCCOM23,284,403$465.7M73.80%
2INTELLIA THERAPEUTICS INCCOM1,615,321$87.9M13.93%
3SURFACE ONCOLOGY INCCOM2,945,453$27.2M4.31%
4SPERO THERAPEUTICS INCCOM1,376,968$26.7M4.23%
5COGENT BIOSCIENCES INCCOM916,196$10.3M1.63%
6SNAP INCCL A150,160$7.5M1.19%
7SYNLOGIC INCCOM2,651,963$5.7M0.91%